Gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced magnetic resonance imaging for evaluating fibrosis regression in chronic hepatitis C patients after direct-acting antiviral

doi:10.3748/wjg.v28.i20.2214

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 20

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5619)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-5) series.

Item

Count

PDF

333

WORD

HTML

2422

Figures (1-3)

551

Tables (1-5)

822

Sum=4222

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

377

Download

1020

Sum=1397

May 28, 2022 (publication date) through Feb 21, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. May 28, 2022; 28(20): 2214-2226
Published online May 28, 2022. doi: 10.3748/wjg.v28.i20.2214

Full Size Figure Download Figure

Figure 1 The study flow chart. HCV: Hepatitis C virus; Gd-EOD-DTPA: Gadolinium ethoxybenzyl diethylenetriamine penta-acetic acid; MRI: Magnetic resonance imaging; IFN: Interferon; SVR: Sustained virological response.

Citation: Li XH, Huang R, Yang M, Wang J, Gao YH, Jin Q, Ma DL, Wei L, Rao HY. Gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced magnetic resonance imaging for evaluating fibrosis regression in chronic hepatitis C patients after direct-acting antiviral. World J Gastroenterol 2022; 28(20): 2214-2226
URL: https://www.wjgnet.com/1007-9327/full/v28/i20/2214.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i20.2214